Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IMS 2023 | EMN20: KRd versus Rd in non-frail, transplant-ineligible patients with NDMM

Mattia D'Agostino • 28 Sep 2023
IMS 2023
Multiple Myeloma Carfilzomib Dexamethasone Lenalidomide
EMN20

In this video, Mattia D’Agostino, MD, University of Turin, Turin, Italy, discusses the results of the EMN20 trial (NCT04096066) which is evaluating carfilzomib, lenalidomide and dexamethasone (KRd) versus Rd in patients with transplant-ineligible newly diagnosed multiple myeloma (NDMM). This interview took place at the 20th International Myeloma Society (IMS) Annual Meeting, held in Athens, Greece.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Mattia D'Agostino

1:07
The second revision of the International Staging System for OS in MM
Mattia D'Agostino • 28 Sep 2023
1:25
Immune reconstitution and vaccination in multiple myeloma
Mattia D'Agostino • 25 Aug 2022
1:38
Using MRD to guide therapy in multiple myeloma
Mattia D'Agostino • 26 Aug 2022
1:55
Predictors of unsustained MRD negativity in multiple myeloma
Mattia D'Agostino • 25 Aug 2022

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals